key: cord-0726772-zqd0eizm authors: Hashim, Hashim Talib title: Convalescent plasma to treat COVID-19: Its challenges in Iraq situation date: 2020-07-16 journal: Ethics Med Public Health DOI: 10.1016/j.jemep.2020.100564 sha: d12bed4e01878c7252ab74ba576a51265c2e527b doc_id: 726772 cord_uid: zqd0eizm nan The therapy's efficacy was found when the viral load was undetectable in many patients who had prior viremia with no significant adverse effects after transfusion [2, 3] . Iraq recorded 1252 confirmed cases of COVID-19 distributed on 18 states on 6 June 2020 and the dominant number was in Baghdad with 665 cases (the number of cases recorded in Iraq since the date of the first case to 6 June was 11098 cases, their details are clarified in Figure 1 ). The medical procedure used in Iraq relies on the symptoms being assisted and the extreme cases being treated with hydroxychloroquine. For the critical cases, the Iraqi National Blood Bank began inviting patients who have recovered from the disease to donate their plasma to be used in treating other patients who need it. After obtaining the consent, the donor should be without symptoms after 14 -28 days, and should be checked to reassure for neutralization of antibody titer and COVID-19 PCR [4] . 400-450 ml of plasma should be used to allow for more donations and leukodepleted plasma should be used. Iraq was faced with a major challenge when the recovered patients were contacted to donate to save the lives of others, only 50 out of 630 patients (7.9%) agreed to be donors and the others refused for many reasons as shown in figure 2 . The plasma is administered as 400 ml in the same day or 200 ml in two doses for each with several hours apart but should be finished within 24 hours. The plasma is only available for serious cases, and life-threatening cases depending on the symptoms [5] . Convalescent plasma as a potential therapy for COVID-19 Effectiveness of convalescent plasma therapy in severe COVID-19 patients Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea Convalescent plasma to treat COVID-19: possibilities and challenges Treatment of 5 critically ill patients with COVID-19 with convalescent plasma While the life-threatening disease conditions are defined as: respiratory failure, septic shock, and/or multiple organ dysfunction or failure.Informed consent is required to undergo convalescent plasma therapy for both the patients and the donors.In Iraq, convalescent plasma therapy provides good results in the treatment of serious cases. So the country's media, government and religious centers have begun to invite recovered people to respond to the invitation from the Iraqi National Blood Bank to donate their plasma, and there is a response, but some of them are still asking for money to offer their plasma, particularly for the rare types of blood.I should state that medical care in Iraq is free for all people and corona patients do not pay any money for their treatment because according to the Iraqi law it is on the government. I declare that I have no conflict of interest or any source of funding.